) This is a new facility to be located in recently renovated space. For several years, one laboratory (Dr. Lees) has served as a resource helping other groups to generate monoclonals. Monoclonal antibodies are a fundamental tool in establishing the precise role of proteins in vivo. The need to provide this as a shared facility is clear. A central facility will ensure maintenance of well tested and reliable myeloma cell lines, serum and other reagents that will greatly improve efficiency and cost effectiveness of the fusions. This will also allow production of antibodies that would otherwise not be generated because of lack of expertise and, in that way, significantly enhance the progress of the research. The facility will operate as a near full service unit using the standard operating protocol defined by the Lees lab. It will conduct most of the steps of monoclonal production including- (1) injection and bleeding of mice, (2) hybridoma fusions, (3) primary ELISA screening, (4) expansion and freezing of primary positive clones (up to 50 per fusion), (5) single cell cloning (up to 10 lines per fusion), (6) expansion and freezing of selected lines (10 vials per line) and (7) large scale production of tissue culture supernatants. Professor Jacqueline Lees will be the facility supervisor. All consumables will be covered by chargeback fees. We propose to charge user fees to cover the cost of purchase, housing, immunization and bleeding of mice 2 P30 CA14051-29 29 Dr. Richard O. Hynes ($250 per antigen) and the cost of the hybridoma fusion and antibody production ($1500 per fusion).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts Institute of Technology
United States
Zip Code
Gocheva, Vasilena; Naba, Alexandra; Bhutkar, Arjun et al. (2017) Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A 114:E5625-E5634
Roper, Jatin; Tammela, Tuomas; Cetinbas, Naniye Malli et al. (2017) In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol 35:569-576
Castleberry, Steven A; Quadir, Mohiuddin A; Sharkh, Malak Abu et al. (2017) Polymer conjugated retinoids for controlled transdermal delivery. J Control Release 262:1-9
Fenouille, Nina; Bassil, Christopher F; Ben-Sahra, Issam et al. (2017) The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med 23:301-313
Chen, Tiffany F; Sazinsky, Stephen L; Houde, Damian et al. (2017) Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. J Mol Biol 429:2528-2541
Lippok, Norman; Villiger, Martin; Albanese, Alexandre et al. (2017) Depolarization signatures map gold nanorods within biological tissue. Nat Photonics 11:583-588
Suzuki, Hiroshi I; Young, Richard A; Sharp, Phillip A (2017) Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis. Cell 168:1000-1014.e15
Doloff, Joshua C; Veiseh, Omid; Vegas, Arturo J et al. (2017) Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nat Mater 16:671-680
Venteicher, Andrew S; Tirosh, Itay; Hebert, Christine et al. (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355:
Gu, Li; Deng, Zhou J; Roy, Sweta et al. (2017) A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer. Clin Cancer Res 23:7312-7323

Showing the most recent 10 out of 829 publications